Literature DB >> 12810628

BRAF as a melanoma susceptibility candidate gene?

Karine Laud1, Caroline Kannengiesser, Marie-Francoise Avril, Agnès Chompret, Dominique Stoppa-Lyonnet, Laurence Desjardins, Alain Eychene, Florence Demenais, Gilbert M Lenoir, Brigitte Bressac-de Paillerets.   

Abstract

A high frequency of activating BRAF somatic mutations have been identified recently in malignant melanoma and nevi indicating that BRAF activation could be an early and critical step in the initiation of melanocytic neoplasia. To determine whether BRAF mutations could be an earlier event occurring at the germline level, we screened the entire BRAF coding region for germline mutations in 80 independent melanoma-prone families or patients with multiple primary melanoma without a familial history. We identified 13 BRAF variants, 4 of which were silent mutations in coding regions and 9 nucleotide substitutions in introns. None of these BRAF variants segregated with melanoma in the 11 melanoma families studied. Moreover, there was no significant difference in the frequency of heterozygotes for BRAF variants between melanoma cases and controls when they were compared. Our data suggest that BRAF is unlikely to be a melanoma susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810628

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

3.  Genetics and genomics of melanoma.

Authors:  Papia Ghosh; Lynda Chin
Journal:  Expert Rev Dermatol       Date:  2009-04-01

4.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

5.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

Review 7.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

8.  Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Authors:  Caroline Kannengiesser; Alain Spatz; Stefan Michiels; Alain Eychène; Philippe Dessen; Vladimir Lazar; Véronique Winnepenninckx; Fabienne Lesueur; Sabine Druillennec; Caroline Robert; Joost J van den Oord; Alain Sarasin; Brigitte Bressac-de Paillerets
Journal:  Mol Oncol       Date:  2008-01-12       Impact factor: 6.603

9.  Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families.

Authors:  Georgia Thodi; Florentia Fostira; Raphael Sandaltzopoulos; George Nasioulas; Anastasios Grivas; Ioannis Boukovinas; Maria Mylonaki; Christos Panopoulos; Mirjana Brankovic Magic; George Fountzilas; Drakoulis Yannoukakos
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

10.  Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.

Authors:  Martin Deichmann; Marianne Thome; Axel Benner; Martin Kirschner; Judith Hassanzadeh; Hjalmar Kurzen
Journal:  BMC Cancer       Date:  2005-06-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.